Up to 35% of aggressive pituitary tumors recur and significantly affect mortality and quality of
life. Management can be challenging and often requires multimodal treatment. Current …

Refractory pituitary adenomas (PAs) are defined as aggressive-invasive PAs characterized
by a high Ki-67 index, rapid growth, frequent recurrence, and resistance to conventional …

Purposes Immunotherapies for solid tumor are gaining traction in the clinic, however, the
immunological landscape of pituitary adenomas (PAs) is not well defined. In the present …

Modulating PD-1 expression can constrain tumor growth. Hodgkin's lymphoma patients
commonly express PD-L1 on tumor cells. We report the case of a 60-year-old male patient …

Aggressive pituitary tumors account for up to 10% of pituitary tumors and are characterized
by resistance to medical treatment and multiple recurrences despite standard therapies …

Context Gonadotroph tumors represent approximatively one-third of anterior pituitary tumors,
but despite their frequency, no medical treatment is currently recommended for them. This …

High-risk pituitary adenomas are aggressive. They show clinical and imaging features
similar to those of carcinomas, including infiltration of the surrounding brain structures, but …

Mismatch repair genes mutS homologs 6/2 (MSH6/2) expressions are involved in tumor
growth and programmed cell death 1 ligand 1 (PD-L1) expression in tumor immunity, but the …

Pituitary adenomas (PAs) are mostly benign endocrine tumors that can be treated by
resection or medication. However, up to 10% of PAs show an aggressive behavior with …

The pituitary tumour microenvironment encompasses a spectrum of non-tumoural cells, such
as immune, stromal or endothelial cells, as well as enzymes and signalling peptides like …